Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of EBIT data on record, last reported at -$122.7 million in Q4 2025.

  • For Q4 2025, EBIT fell 40.33% year-over-year to -$122.7 million; the TTM value through Dec 2025 reached -$363.4 million, down 21.52%, while the annual FY2025 figure was -$363.4 million, 21.52% down from the prior year.
  • EBIT reached -$122.7 million in Q4 2025 per VRDN's latest filing, down from -$40.0 million in the prior quarter.
  • Across five years, EBIT topped out at -$14.1 million in Q3 2021 and bottomed at -$122.7 million in Q4 2025.
  • Average EBIT over 5 years is -$56.5 million, with a median of -$53.6 million recorded in 2023.
  • The widest YoY moves for EBIT: up 67.9% in 2021, down 182.37% in 2021.
  • A 5-year view of EBIT shows it stood at -$29.1 million in 2021, then plummeted by 68.72% to -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then dropped by 22.38% to -$87.5 million in 2024, then crashed by 40.33% to -$122.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$122.7 million in Q4 2025, -$40.0 million in Q3 2025, and -$106.8 million in Q2 2025.